Brokerages expect Apellis Pharmaceuticals Inc (NASDAQ:APLS) to post ($1.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Apellis Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.11) and the highest is ($0.93). Apellis Pharmaceuticals reported earnings of ($0.64) per share in the same quarter last year, which would suggest a negative year over year growth rate of 62.5%. The business is scheduled to announce its next earnings results on Tuesday, November 12th.
On average, analysts expect that Apellis Pharmaceuticals will report full-year earnings of ($4.07) per share for the current fiscal year, with EPS estimates ranging from ($4.26) to ($3.77). For the next fiscal year, analysts expect that the company will report earnings of ($4.38) per share, with EPS estimates ranging from ($4.53) to ($4.23). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Apellis Pharmaceuticals.
Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.98) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.18).
In other Apellis Pharmaceuticals news, COO Pascal Deschatelets sold 42,460 shares of the stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $24.82, for a total value of $1,053,857.20. Also, CEO Cedric Francois sold 10,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $26.80, for a total transaction of $268,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 57,460 shares of company stock worth $1,454,807. Company insiders own 10.60% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Apellis Pharmaceuticals by 21.0% during the second quarter. BlackRock Inc. now owns 4,502,117 shares of the company’s stock worth $114,085,000 after acquiring an additional 781,085 shares in the last quarter. Jennison Associates LLC increased its position in shares of Apellis Pharmaceuticals by 57.2% during the second quarter. Jennison Associates LLC now owns 923,244 shares of the company’s stock worth $23,395,000 after acquiring an additional 335,863 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the second quarter worth $4,361,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Apellis Pharmaceuticals during the second quarter worth $3,276,000. Finally, Point72 Asset Management L.P. increased its position in shares of Apellis Pharmaceuticals by 20.2% during the second quarter. Point72 Asset Management L.P. now owns 401,104 shares of the company’s stock worth $10,164,000 after acquiring an additional 67,475 shares in the last quarter. Institutional investors own 63.44% of the company’s stock.
Shares of NASDAQ APLS opened at $25.56 on Wednesday. The company’s 50 day simple moving average is $27.04 and its 200 day simple moving average is $23.82. Apellis Pharmaceuticals has a fifty-two week low of $11.45 and a fifty-two week high of $33.18. The firm has a market capitalization of $1.47 billion, a P/E ratio of -10.92 and a beta of 0.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.67 and a quick ratio of 8.67.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Further Reading: What is the strike price in options trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.